文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

多参数MRI、PET/CT与活检对前列腺内放射性复发灶识别与勾画的价值

The Importance of Multiparametric Magnetic Resonance Imaging, Positron Emission Tomography/Computed Tomography, and Biopsy for Identifying and Delineating the Extent of Intraprostatic Radiorecurrent Prostate Cancer: A Secondary Analysis of the F-SHARP Clinical Trial.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2025-03-06

本文为F-SHARP临床试验的二次分析,纳入62例接受挽救性高剂量率近距离治疗的前列腺内放射性复发(IPRR)患者,比较MRI、PET/CT与活检对复发灶识别及范围勾画的作用。MRI检测IPRR的敏感性为91.8%,PET/CT为85.5%;70.5%与73.8%的患者在MRI与PET/CT定义靶区外存在活检证实的癌灶,仅用影像勾画靶区会使63.9%的患者遗漏复发完整范围。

要点

  • MRI检测IPRR敏感性91.8%,PET/CT为85.5%。
  • 70.5%患者在MRI定义靶区外、73.8%在PET/CT定义靶区外有活检证实的癌。
  • 仅用影像勾画近距离治疗靶区会遗漏63.9%患者的完整复发范围。

核心结论

  • MRI与PET/CT虽有价值,但充分活检是局灶挽救治疗时避免遗漏影像隐匿前列腺内侵犯范围的必需工具。

研究设计与样本

  • F-SHARP 1/2期临床试验的二次分析,纳入62例接受挽救性高剂量率近距离治疗的患者。
  • 用各影像模态勾画IPRR,并以活检定义前列腺受累区域;用精确二项分布估计MRI与PET/CT检测IPRR的敏感性。
  • 用精确条件logistic回归比较MRI与PET/CT识别的肿瘤与活检受累区域(金标准),并估计影像定义靶区外前列腺受累患者的比例。

主要发现

  • 检测IPRR的敏感性MRI为91.8%,PET/CT为85.5%。
  • 多数患者在MRI定义靶区外(70.5%)和PET/CT定义靶区外(73.8%)存在活检证实的癌。
  • 仅用影像勾画近距离治疗靶区会使63.9%的患者遗漏复发完整范围。

关键数值与推荐

  • MRI检测IPRR敏感性91.8%,PET/CT为85.5%。
  • MRI定义靶区外活检证实癌者占70.5%,PET/CT定义靶区外者占73.8%。
  • 仅影像勾画靶区遗漏完整复发范围者占63.9%。

临床怎么用

  • 原文结论为:MRI与PET/CT虽有价值,但充分活检是局灶挽救治疗时避免遗漏影像隐匿前列腺内侵犯的必需工具。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Up to 50% of clinical recurrences after curative-intent prostate cancer radiation are intraprostatic radiorecurrences (IPRRs). Salvage local therapy (SLT) is increasingly offered, particularly as focal SLT, to reduce toxicity due to prior radiation. Limited data exist on the relative value of magnetic resonance imaging (MRI), positron emission tomography/computed tomography (PET/CT), and biopsy on SLT target delineation. We compared MRI, PET/CT, and biopsy in patients with IPRRs and the impact each modality has on identifying IPRRs and defining the extent of prostatic involvement. METHODS AND MATERIALS: We performed a secondary analysis of 62 patients enrolled in a phase 1/2 clinical trial of salvage high-dose-rate brachytherapy. The IPRR was delineated using each imaging modality and by defining the involved regions of the prostate on biopsy. The exact binomial distribution was used to estimate the sensitivity of MRI and PET/CT to detect the IPRR. Exact conditional logistic regression was used to compare the tumor identified by MRI and PET/CT with the areas of biopsy involvement (gold standard) and estimate the proportion of patients with prostatic involvement outside of the image-defined targets. RESULTS: The sensitivity for detecting the IPRR was 91.8% for MRI and 85.5% for PET/CT. Most patients had biopsy-proven cancer outside of the MRI-defined (70.5%) and PET/CT-defined (73.8%) target. Delineating the brachytherapy target using imaging only would have missed the full extent of recurrence in 63.9%. CONCLUSIONS: Although MRI and PET/CT are valuable, a thorough biopsy is a mandatory tool to avoid missing areas of imaging-occult prostatic involvement when delivering focal SLT.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Venkatesulu B, Adams W, Joel R, et al. The Importance of Multiparametric Magnetic Resonance Imaging, Positron Emission Tomography/Computed Tomography, and Biopsy for Identifying and Delineating the Extent of Intraprostatic Radiorecurrent Prostate Cancer: A Secondary Analysis of the F-SHARP Clinical Trial. Int J Radiat Oncol Biol Phys. 2025. PMID: 40057285. doi:10.1016/j.ijrobp.2025.02.042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。